Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Haemonetics (HAE) Gets a Buy from BTIG

Tipranks - Tipranks - Sat Feb 21, 11:16AM CST

BTIG analyst Marie Thibault maintained a Buy rating on Haemonetics on February 18 and set a price target of $88.00.

President's Day Sale - 70% Off

Thibault covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Ceribell, Inc., and Boston Scientific. According to TipRanks, Thibault has an average return of -12.6% and a 33.53% success rate on recommended stocks.

In addition to BTIG, Haemonetics also received a Buy from Mizuho Securities’s Anthony Petrone in a report issued on February 10. However, on February 7, TipRanks – xAI reiterated a Hold rating on Haemonetics (NYSE: HAE).

See today’s best-performing stocks on TipRanks >>

Based on Haemonetics’ latest earnings release for the quarter ending December 27, the company reported a quarterly revenue of $338.97 million and a net profit of $44.74 million. In comparison, last year the company earned a revenue of $348.54 million and had a net profit of $37.49 million

Read More on HAE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).